Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
A great find Sarahrodhz
Welcome to the forum - and pointing us in the right direction on your 1st post ;-)
just had a small top up charged full of ask 64p well still happy gla
So Pharmaxis or AZN or both could be licensed to develop this drug?
From 2015 but interesting none the less:
Who is Synairgen?
Based in the UK and publicly traded, the business focuses primarily on severe asthma and COPD using differentiating human biology BioBank platform and world-renowned international academic Key Opinion Leader network to discover and develop novel therapies for respiratory disease. The company’s current market capitalization stands at $40m.
Southampton General Hospital Facility
The firm maintains a facility at Southampton General Hospital for ongoing research using in vitro and ex vivo models to progress opportunities into clinical development. The BioBank of human samples is used in these models to increase confidence in the likelihood of successful drug development.
Licensing Deals
The company has inked different licensing deals, such as a collaboration in 2015 with Pharmaxis to develop an oral LOXL2 inhibitor to reduce fibrosis in patients with idiopathic pulmonary fibrosis (IPF). By 2017, this agreement was updated as Synairgen received 5 million UK Pounds in upfront payment and circa 17% of any future net partnering proceeds from all fibrotic indications.
Southampton uni hold the patent but SNG have exclusive license. Patent for the formulation was gained in 2009 in the US. It’s well protected, they are not idiots.
" Now we are talking about to scale up to hundreds of thousands and millions of doses later this year."
Great find SGD27
Best part of the interview for me:
" Now we are talking about to scale up to hundreds of thousands and millions of doses later this year."
So I think there is no doubt now.
If we have success, Synairgen with the help of many others to manufacture under license will be winners.
@oilornothing Thanks for the clarification.
This is for the USA :
https://www.ipgroupplc.com/media/portfolio-news/2009/2009-09-04b
with similar for Europe.
GB201004144 which claims priority is assigned to Synairgen Res Ltd.
But the addresses of the inventors are all Southampton, assuming this was spun out?
fab BBC interview...very clear explanations on how this is different , WHO trials /Synairgen and production queries.
Noe I really want this to work more than ever. A UK hospital, not a massive corporation has found the answer. What an amazing news story that would be if it all went our way.
#havefaith
Direct to lung treatment.
Place your bets gents!
Interferon by injection requires massive doses due to its half-life which isn’t good. Nebuliser is the quickest and most efficient method. That’s info from knobby.
stand corrected. Apologies
Southampton university hold the patent for the inhaled form.
This has been licenced by synairgen.
So in a nutshell we are betting on Synairgens inhaler delivering faster results than an injection or powder form, which
in theory it should.
If so they hold the patent and although they may not manufacture in large quantities many companies could.....at a price to us all :)
Patent link below:
https://patents.google.com/patent/ES2592528T3/en?assignee=synairgen&oq=synairgen
Interesting it is actually worded as 'influenza like illnesses' which I assume Covid-19 ticks the symptoms box as described in the patent.
It is very complicated that's for sure
Interferon beta-1a is a cytokine in the interferon family used to treat multiple sclerosis. It is produced by mammalian cells, while interferon beta-1b is produced in modified E. coli. Some claims have been made that Interferon's produce about an 18-38% reduction in the rate of MS relapses.
The "Interferon Beta-1A Market" globally is a standout amongst the most emergent and astoundingly approved sectors. This worldwide market has been developing at a higher pace with the development of imaginative frameworks and a developing end-client tendency.
https://www.openpr.com/news/1994567/interferon-beta-1a-market-share-trends-and-analysis-growth
Ok...think I got it!!!
GOOGLE PATENTS and search#
Interferon beta for use in the treatment of lower respiratory diseases caused by influenza
(Maybe someone could post me a link)
That's a worldwide patent!!
Google "synairgen ifn patent"
Obviously SNG have their inhaled formula patented...nobody else can walk in and replicate...they've been working on it for years
There are various patents around Interferon Beta for different companies..Farn has a load on the same molecule...you'll have to be a Pharma to understand the detail
@ATBD
"failed to mention whether this therapy was owned by Synairgen (I'm guessing not)"
You're right, "not". I don't think there was any attempt to disguise this.
"what is to stop another pharma from ..."
I've asked this before, and someone here said it's well covered by patents for the inhaled formulation - can't remember details, countries etc but includes USA if I recall correctly. Anyone confirm?
If you go to GOOGLE PATENTS patents.google
Looks like Synairgen have a patent for Inteferon Beta but I cant 100% see how this relates to what the company has today. Maybe someone else can shed light?
SEARCH:
Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly